Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2550]

WCLC 2024: LUMINOSITY trial demonstrates telisotuzumab vedotin shows durable response in Asian patients with c-Met protein-overexpressing EGFR WT nonsquamous NSCLC

WCLC 2024: LUMINOSITY trial demonstrates telisotuzumab vedotin shows durable response in Asian patients with c-Met...

WCLC 2024: Aumolertinib maintenance after chemoradiotherapy in stage III non-small cell lung cancer improves PFS compared to placebo

WCLC 2024: Aumolertinib maintenance after chemoradiotherapy in stage III non-small cell lung cancer improves PFS...

WCLC 2024: Osimertinib with savolitinib demonstrates stronger efficacy than osimertinib alone in patients who do not respond well to EGFR-TKIs therapy

WCLC 2024: Osimertinib with savolitinib demonstrates stronger efficacy than osimertinib alone in patients who do...

WCLC 2024: Zongertinib demonstrates promising efficacy in patients with HER2-mutant NSCLC: Primary phase Ib analysis of beamion LUNG-1

WCLC 2024: Zongertinib demonstrates promising efficacy in patients with HER2-mutant NSCLC: Primary phase Ib...

WCLC 2024: Breakthrough therapy BAY 2927088 demonstrates ‘rapid, substantial and durable responses’ in patients with HER2-mutant NSCLC

WCLC 2024: Breakthrough therapy BAY 2927088 demonstrates ‘rapid, substantial and durable responses’ in patients...

WCLC 2024: Results from the FURTHER trial demonstrate firmonertinib is a promising potential therapy for patients with NSCLC with EGFR PACC mutations

WCLC 2024: Results from the FURTHER trial demonstrate firmonertinib is a promising potential therapy for patients...

WCLC 2024: Amivantamab-vmjw plus lazertinib show strong favourable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer

WCLC 2024: Amivantamab-vmjw plus lazertinib show strong favourable overall survival trend versus osimertinib in...

WCLC 2024: Artificial intelligence method transforms gene mutation prediction in lung cancer: DeepGEM data releases at IASLC 2024 World Conference on Lung Cancer

WCLC 2024: Artificial intelligence method transforms gene mutation prediction in lung cancer: DeepGEM data...

WCLC 2024: Antibody–drug conjugate I-DXd shows clinically meaningful response in patients with extensive-stage small cell lung cancer

WCLC 2024: Antibody–drug conjugate I-DXd shows clinically meaningful response in patients with extensive-stage...

WCLC 2024: IASLC Global Survey on biomarker testing reveals progress and persistent barriers in lung cancer biomarker testing

WCLC 2024: IASLC Global Survey on biomarker testing reveals progress and persistent barriers in lung cancer...

More from ecancer